SCHEMBL4280129

SCHEMBL4280129

COC(=O)c1cccc(NC(=O)/C=C/c2ccc(Sc3ccc(F)cc3)cc2Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.51
SMN1; SMN2 Q16637 8/20 0.51
TP53 P04637 2/20 0.51
MEN1 O00255 8/20 0.48
KMT2A Q03164 8/20 0.48
LMNA P02545 3/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPK1 P28482 2/20 0.48
RAB9A P51151 9/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C19 P33261 2/20 0.47
NPC1 O15118 8/20 0.47
PKM P14618 1/20 0.47
NFKB1 P19838 1/20 0.47
MAOB P27338 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
KDM4E B2RXH2 1/20 0.46
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4280130 1.00 MAPT (0.51) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL13879594 0.89 MAPT (0.48) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL4277201 0.89 MAPT (0.49) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL4277198 0.89 MAPT (0.49) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL13879683 0.87 MAOB (0.53) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL13879593 0.78 LTB4R (0.49) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4281398 0.77 MAPT (0.45) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL4281400 0.77 MAPT (0.45) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL27751383 0.73 LTB4R (0.42) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL4278685 0.73 MIF (0.44) MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 MAPT 4203/4885SMN1; SMN2 2091/4885TP53 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.